Aaron Wealth Advisors LLC Grows Stock Position in Pfizer Inc. $PFE

Aaron Wealth Advisors LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 109.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,444 shares of the biopharmaceutical company’s stock after buying an additional 21,152 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Pfizer were worth $1,031,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Pfizer during the 2nd quarter worth $2,270,157,000. Amundi raised its holdings in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Vanguard Group Inc. lifted its position in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after purchasing an additional 5,662,309 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Pfizer by 84.9% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock valued at $183,302,000 after purchasing an additional 3,472,240 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on PFE shares. Morgan Stanley decreased their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Bank of America dropped their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.22.

Pfizer Trading Down 3.3%

Pfizer stock opened at $25.56 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The firm’s 50 day moving average price is $25.11 and its 200-day moving average price is $24.81. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock has a market cap of $145.34 billion, a P/E ratio of 14.86 and a beta of 0.46.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.